Announcements Trials
Browse Landscape

Status

No longer available 2

Sponsor Class

INDUSTRY 2

Study Type

Interventional 20Expanded_access 2Observational 1

Sponsor

Cancer Type

Sarcoma 2Thoracic 1Other solid neoplasm 1Genitourinary 1

Conditions

Sarcoma 2Sarcoma, Synovial 1Rhabdoid Tumor 1Neoplasms 1Mesothelioma, Malignant 1Desmoplastic Small Round Cell Tumor 1Chondrosarcoma 1Carcinoma, Renal Cell 1

Interventions

nilotinib 5dabrafenib 4Nivolumab 4Afatinib 4trametinib 3regorafenib 3midostaurin 3elotuzumab 3TIC10 compound 3Sunitinib 3Prednisone 3Capecitabine 3Abiraterone Acetate 33-Iodobenzylguanidine 3venetoclax 2tucatinib 2tempol 2tazemetostat 2talquetamab 2talimogene laherparepvec 2ruxolitinib 2pomalidomide 2olaparib 2niraparib 2leronlimab 2lenvatinib 2ibrutinib 2gilteritinib 2ceritinib 2brexucabtagene autoleucel 2

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

2 trials
RecentStart dateEnrollment
INDUSTRY × Expanded_access × tazemetostat × Clear all
NCT04225429 2024-10-01

Tazemetostat Expanded Access Program for Adults With Epithelioid Sarcoma

Ipsen

No longer available
Sarcoma

Neoplasms, Sarcoma

NCT03874455 2024-03-22

Tazemetostat Expanded Access Program for Adults With Solid Tumors

Ipsen

No longer available
GenitourinaryOther solid neoplasmSarcomaThoracic

Mesothelioma, Malignant, Carcinoma, Renal Cell, Chondrosarcoma, Sarcoma, Sarcoma, Synovial, Rhabdoid Tumor, Desmoplastic Small Round Cell Tumor

Data powered by HemOnc (CC BY 4.0) Colophon âš¡